AeroPace System
Lungpacer Medical USA, Inc. · Decision date Sep 23, 2025
What did the FDA approve?
FDA records P240012/S002 as a supplement to PMA P240012, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Sep 23, 2025.
FDA approval order statement
Approval of catheter manifold changes, flex circuit changes, and addition of dilator size.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Anesthesiology
- Decision date
- Sep 23, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P240012/S002
- Regulatory pathway
- PMA supplement
- Applicant
- Lungpacer Medical USA, Inc.
- Product code
- SDL
- Decision code
- APPR
- Decision date
- Sep 23, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Transvenous temporary phrenic nerve stimulator.
- Applicant
- Lungpacer Medical USA, Inc.
- Product code
- SDL
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240012. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240012 · Original PMA
AeroPace System
P240012/S002 received
Application receipt date recorded by FDA.
P240012/S002 · FDA decision
Real-Time Process
P240012/S003 · Related supplement
AeroPace System
P240012/S004 · Related supplement
AeroPace System
P240012/S005 · Related supplement
AeroPace System
P240012/S006 · Related supplement
AeroPace System
P240012/S007 · Related supplement
AeroPace System
P240012/S008 · Related supplement
AeroPace System
Timeline entries are records held by MedtechLedger for P240012. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240012
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
AeroPace SystemP240012 | Lungpacer Medical USA, Inc. | PMA approval | Dec 4, 2024 | FDA |
AeroPace SystemP240012/S003 | Lungpacer Medical USA, Inc. | PMA supplement | Sep 29, 2025 | FDA |
AeroPace SystemP240012/S004 | Lungpacer Medical USA, Inc. | PMA supplement | Jan 14, 2026 | FDA |
AeroPace SystemP240012/S005 | Lungpacer Medical USA, Inc. | PMA supplement | Feb 20, 2026 | FDA |
AeroPace SystemP240012/S006 | Lungpacer Medical USA, Inc. | PMA supplement | Jun 22, 2026 | FDA |
AeroPace SystemP240012/S007 | Lungpacer Medical USA, Inc. | PMA supplement | Jun 22, 2026 | FDA |
AeroPace SystemP240012/S008 | Lungpacer Medical USA, Inc. | PMA supplement | Sep 25, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Lungpacer Medical USA, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 260 Sierra Dr., Suite 116, Exton, PA, 19341
Sources and methodology
- Original FDA record: P240012/S002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





